236 related articles for article (PubMed ID: 31520102)
21. Hyperacute peripheral neuropathy is a predictor of oxaliplatin-induced persistent peripheral neuropathy.
Tanishima H; Tominaga T; Kimura M; Maeda T; Shirai Y; Horiuchi T
Support Care Cancer; 2017 May; 25(5):1383-1389. PubMed ID: 27921224
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Oncology Multidisciplinary Research Group (GERCOR).
Maindrault-Goebel F; de Gramont A; Louvet C; André T; Carola E; Gilles V; Lotz JP; Tournigand C; Mabro M; Molitor JL; Artru P; Izrael V; Krulik M
Ann Oncol; 2000 Nov; 11(11):1477-83. PubMed ID: 11142489
[TBL] [Abstract][Full Text] [Related]
23. [Prevention of oxaliplatin-induced neuropathy by carbamazepine. A pilot study].
Eckel F; Schmelz R; Adelsberger H; Erdmann J; Quasthoff S; Lersch C
Dtsch Med Wochenschr; 2002 Jan; 127(3):78-82. PubMed ID: 11797144
[TBL] [Abstract][Full Text] [Related]
24. Persistent prevention of oxaliplatin-induced peripheral neuropathy using calmangafodipir (PledOx
Glimelius B; Manojlovic N; Pfeiffer P; Mosidze B; Kurteva G; Karlberg M; Mahalingam D; Buhl Jensen P; Kowalski J; Bengtson M; Nittve M; Näsström J
Acta Oncol; 2018 Mar; 57(3):393-402. PubMed ID: 29140155
[TBL] [Abstract][Full Text] [Related]
25. The Kampo medicine, Goshajinkigan, prevents neuropathy in patients treated by FOLFOX regimen.
Nishioka M; Shimada M; Kurita N; Iwata T; Morimoto S; Yoshikawa K; Higashijima J; Miyatani T; Kono T
Int J Clin Oncol; 2011 Aug; 16(4):322-7. PubMed ID: 21258836
[TBL] [Abstract][Full Text] [Related]
26. Clinical management of oxaliplatin-associated neurotoxicity.
Grothey A
Clin Colorectal Cancer; 2005 Apr; 5 Suppl 1():S38-46. PubMed ID: 15871765
[TBL] [Abstract][Full Text] [Related]
27. Preventive effect of traditional Japanese medicine on neurotoxicity of FOLFOX for metastatic colorectal cancer: a multicenter retrospective study.
Hosokawa A; Ogawa K; Ando T; Suzuki N; Ueda A; Kajiura S; Kobayashi Y; Tsukioka Y; Horikawa N; Yabushita K; Fukuoka J; Sugiyama T
Anticancer Res; 2012 Jul; 32(7):2545-50. PubMed ID: 22753712
[TBL] [Abstract][Full Text] [Related]
28. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study.
Tournigand C; Cervantes A; Figer A; Lledo G; Flesch M; Buyse M; Mineur L; Carola E; Etienne PL; Rivera F; Chirivella I; Perez-Staub N; Louvet C; André T; Tabah-Fisch I; de Gramont A
J Clin Oncol; 2006 Jan; 24(3):394-400. PubMed ID: 16421419
[TBL] [Abstract][Full Text] [Related]
29. A phase II study of bevacizumab with modified OPTIMOX1 as first-line therapy for metastatic colorectal cancer: the TCOG-GI 0802 study.
Nakayama N; Sato A; Tanaka S; Shimada K; Konishi K; Sasaki E; Hibi K; Ichikawa H; Kikuchi Y; Sakuyama T; Sekikawa T; Hayashi K; Nishina H;
Invest New Drugs; 2015 Aug; 33(4):954-62. PubMed ID: 25937430
[TBL] [Abstract][Full Text] [Related]
30. Prevalence of Oxaliplatin-induced Chronic Neuropathy and Influencing Factors in Patients with Colorectal Cancer in Iran.
Shahriari-Ahmadi A; Fahimi A; Payandeh M; Sadeghi M
Asian Pac J Cancer Prev; 2015; 16(17):7603-6. PubMed ID: 26625769
[TBL] [Abstract][Full Text] [Related]
31. Second-line chemotherapy with weekly oxaliplatin and high-dose 5-fluorouracil with folinic acid in metastatic colorectal carcinoma: a Hellenic Cooperative Oncology Group (HeCOG) phase II feasibility study.
Janinis J; Papakostas P; Samelis G; Skarlos D; Papagianopoulos P; Fountzilas G
Ann Oncol; 2000 Feb; 11(2):163-7. PubMed ID: 10761750
[TBL] [Abstract][Full Text] [Related]
32. Predicting acute and persistent neuropathy associated with oxaliplatin.
Alejandro LM; Behrendt CE; Chen K; Openshaw H; Shibata S
Am J Clin Oncol; 2013 Aug; 36(4):331-7. PubMed ID: 22547012
[TBL] [Abstract][Full Text] [Related]
33. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study.
Rothenberg ML; Cox JV; Butts C; Navarro M; Bang YJ; Goel R; Gollins S; Siu LL; Laguerre S; Cunningham D
Ann Oncol; 2008 Oct; 19(10):1720-6. PubMed ID: 18550577
[TBL] [Abstract][Full Text] [Related]
34. A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer.
Lévi F; Misset JL; Brienza S; Adam R; Metzger G; Itzakhi M; Caussanel JP; Kunstlinger F; Lecouturier S; Descorps-Declère A
Cancer; 1992 Feb; 69(4):893-900. PubMed ID: 1735081
[TBL] [Abstract][Full Text] [Related]
35. Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen.
André T; Bensmaine MA; Louvet C; François E; Lucas V; Desseigne F; Beerblock K; Bouché O; Carola E; Merrouche Y; Morvan F; Dupont-André G; de Gramont A
J Clin Oncol; 1999 Nov; 17(11):3560-8. PubMed ID: 10550155
[TBL] [Abstract][Full Text] [Related]
36. Addition of gabapentin to a modified FOLFOX regimen does not reduce oxaliplatin-induced neurotoxicity.
Mitchell PL; Goldstein D; Michael M; Beale P; Friedlander M; Zalcberg J; White S; Thomson JA; Clarke S
Clin Colorectal Cancer; 2006 Jul; 6(2):146-51. PubMed ID: 16945171
[TBL] [Abstract][Full Text] [Related]
37. High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7).
Maindrault-Goebel F; de Gramont A; Louvet C; André T; Carola E; Mabro M; Artru P; Gilles V; Lotz JP; Izrael V; Krulik M;
Eur J Cancer; 2001 May; 37(8):1000-5. PubMed ID: 11334725
[TBL] [Abstract][Full Text] [Related]
38. Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial.
Lévi FA; Zidani R; Vannetzel JM; Perpoint B; Focan C; Faggiuolo R; Chollet P; Garufi C; Itzhaki M; Dogliotti L
J Natl Cancer Inst; 1994 Nov; 86(21):1608-17. PubMed ID: 7932825
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and tolerability of oxaliplatin plus irinotecan 5-fluouracil and leucovorin regimen in advanced stage colorectal cancer patients pretreated with irinotecan 5-fluouracil and leucovorin.
Stathopoulos GP; Rigatos SK; Stathopoulos JG; Xynotroulas JP; Dimou E
Am J Clin Oncol; 2005 Dec; 28(6):565-9. PubMed ID: 16317265
[TBL] [Abstract][Full Text] [Related]
40. [FOLFOX].
Mishima H; Ikenaga M; Tsujinaka T; Yasui M; Kashiwazaki M; Miyazaki M; Hirao M; Fujitani K; Nakamori S
Gan To Kagaku Ryoho; 2006 Jul; 33(7):911-4. PubMed ID: 16835479
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
